Cerebrolysin: A Heavily Studied Brain Peptide Whose Best Trials Came Up Short

Cerebrolysin is one of the few compounds in the “nootropic peptide” (brain-boosting peptide) world that has actually been studied in a serious way. Most research peptides have very little human data. This one is different: it has a real history as a prescription drug in other countries, several randomized controlled trials (studies where people are randomly assigned to the drug or a comparison, the gold standard for testing whether something works), and several Cochrane systematic reviews (independent, careful round-ups of all the trustworthy evidence). That sounds encouraging, but the picture changes once you look at what those trials actually found. The biggest and most carefully run test of its main use came back neutral, and the most independent summaries of the evidence describe the benefits as modest at best, or simply uncertain. This profile walks through what Cerebrolysin is, what people claim it does, and what the strongest evidence really shows.

What it is

Cerebrolysin is not one single molecule. It is a complex mixture made by using pancreatic enzymes (digestive proteins) to break down purified pig (porcine) brain protein in a standardized way. The product you buy is usually listed at 215.2 mg/mL of peptide and amino-acid material. According to manufacturer and review write-ups, it is roughly three-quarters free amino acids and one-quarter small peptides, with the peptides smaller than about 10,000 daltons (a unit for measuring molecular weight). Keep in mind that this split is just an approximate figure from reviews and the manufacturer, not a tightly audited spec. Because the whole thing is a peptide-and-amino-acid mixture, it has to be given by injection or IV drip (straight into a vein) — swallowing it as a pill wouldn’t work, since your stomach would just digest it.

The idea behind it is that the peptide portion imitates the body’s own neurotrophic factors (natural proteins that help brain cells grow, survive and connect), such as BDNF, GDNF, NGF and CNTF, and flips on signals linked to protecting the brain and helping it rewire itself. But there are real reasons to be careful here. Reference summaries point out that the exact effects at the molecular level “are not clear,” and that BDNF only lasts about ten minutes in the bloodstream — which makes you wonder how an injected mixture could keep that kind of signaling going. More importantly, Cerebrolysin has no single, defined active ingredient. Its makeup is known to change from batch to batch and from maker to maker, and the active parts have never been fully pinned down. That missing, clearly-defined active ingredient is one of the main reasons it doesn’t fit the rules used to approve drugs in the United States.

The claims

The maker’s officially registered uses are all about blood-flow and brain conditions: Alzheimer’s-type dementia, vascular dementia (dementia caused by reduced blood flow to the brain), stroke, and head trauma. On top of those, it has been studied for recovery after traumatic brain injury, for regaining movement and language after a stroke, and for thinking problems in schizophrenia.

On the gray market (the unregulated, semi-legal corner where these products are sold without oversight), it is pushed much harder — as a general “nootropic,” a brain enhancer, a brain protector, and a tool for “brain repair” or anti-aging in people who are perfectly healthy. Those last claims have no solid evidence behind them. The independent Alzheimer’s Drug Discovery Foundation puts it bluntly: there are zero clinical studies on preventing dementia or on improving thinking in healthy adults.

The evidence

Stroke is where Cerebrolysin has been put to its toughest test, and the result is basically negative. The CASTA trial (Heiss et al., 2012) was the largest randomized controlled trial, with 1,070 patients who had just had an ischemic stroke (a stroke caused by a blocked blood vessel), mostly at centers in China. Its main goal — a combined score of disability and brain function at day 90 — showed no real difference. A post-hoc analysis (extra number-crunching done after the fact, not the original plan) hinted at fewer deaths in the Cerebrolysin group and a possible benefit in the most severely affected patients. But post-hoc findings can only suggest ideas to test later; they can’t make up for a main result that came back flat.

The 2023 Cochrane review of Cerebrolysin for ischemic stroke combined seven trials and 1,773 participants. Based on moderate-certainty evidence, it found no effect on death from any cause. It also found that non-fatal serious side effects may go up, with a relative risk of 2.39 (95% CI 1.10 to 5.23) — again on moderate-certainty evidence. (A relative risk of 2.39 means the rate was a bit more than double; the range in parentheses is where the true number most likely sits.) That is an important counterweight to the usual “well-tolerated” pitch.

A more upbeat stroke result comes from the CARS trial (Muresanu et al., 2016), which found a benefit for recovering arm movement after a stroke. But CARS was small (about 205 patients analyzed), it was paid for by EVER Neuro Pharma (the company that makes the drug), and several of its authors had financial ties to that company.

Vascular dementia. The 2019 Cochrane review covered six studies and 597 participants, and it did report benefits for thinking, for the share of people who responded, and for overall function. The catch: all of that rested on very-low-quality evidence, weakened by imprecision (results too fuzzy to trust), indirectness (the studies didn’t quite match the question being asked) and serious risk of bias. The reviewers themselves called the effect modest and said it may not actually matter much to people living with dementia.

Alzheimer’s disease. A handful of small trials have shown modest bumps on standard tests of thinking. The ADDF’s overview of the research (three meta-analyses and six RCTs) describes the effect in mild-to-moderate Alzheimer’s as modest, smaller than the benefit from approved Alzheimer’s drugs, mostly coming from small or unconfirmed studies, and with no prevention data whatsoever.

Traumatic brain injury. A 2018 meta-analysis (Ghaffarpasand et al.) pooled five studies and 5,685 participants and found favorable combined results on outcome scales. The big caveat: four of those five studies were non-randomized cohort designs (they simply followed groups of patients rather than randomly assigning treatment, which makes the results easier to skew). The authors themselves rated the evidence only at “Level II,” admitting there were no high-quality randomized trials.

Step back and the pattern is consistent. There is no large, independent, confirming trial that hit its main goal for any condition. The one large, rigorous stroke trial came back neutral. The encouraging signals lean heavily on manufacturer money, post-hoc subgroups, scales measuring stand-in or rehab outcomes rather than the real target, non-randomized data, and evidence the reviewers themselves rate as low or very-low certainty. For context, independent science-watchdog reporting has also dug into parts of Cerebrolysin’s animal-study literature and into some authors connected to the manufacturer. That reporting is opinion-style and not peer-reviewed, so treat it as background rather than fact — but it is part of why the evidence gets a skeptical eye. All of this is why the grade here is “Preliminary human,” near the lower end of that band: there is far more human data than for a typical research peptide, but it does not confirm the benefits being marketed.

Safety and side effects

In trials and in real-world use, the reported side effects are usually mild and short-lived: dizziness or vertigo, a feeling of heat, sweating, headache and nausea. Agitation, trouble sleeping and confusion have been tied to a stimulant-like effect, and injecting it too fast can cause heart palpitations (a racing or fluttering heartbeat). The prescribing information lists reasons not to use it, including epilepsy, kidney disease and hypersensitivity (a strong allergic-type reaction); the manufacturer’s own documents word this more narrowly as status epilepticus (a prolonged, dangerous seizure), grand mal epilepsy and severe kidney impairment.

Two cautions deserve real weight. First, the 2023 Cochrane review’s finding of a possible rise in non-fatal serious side effects muddies the usual “safe and well-tolerated” message. Second, the long-term safety — and the specific risks of an injected product made from pig brain — has not been well studied in independent research. Those risks include immunogenicity (your immune system reacting to the foreign material) and theoretical worries about transmissible agents (the chance of passing along an infectious particle). And on the gray market, where vials are sold as “research chemicals” with no oversight at all, contamination, lack of sterility and outright counterfeiting are real, added concerns.

Legal and regulatory status

Cerebrolysin is not approved by the FDA, and it is not legal to sell or market in the United States. It does appear in the FDA’s substance registry, but that listing comes with an explicit note that it does not mean the agency reviewed or approved anything. The ADDF likewise confirms it is not approved in the US for any condition. Claims that it has an FDA orphan-drug designation (a special status for treatments aimed at rare diseases) appear to be false — a search turns up none, and the orphan designations people point to actually belong to completely different drugs.

Outside the US, it is a prescription medicine in Austria, Russia, China and South Korea, and is reportedly registered in 50 or more countries, mostly in Eastern Europe, Asia and Latin America — though that count comes from secondary and manufacturer sources, not an independent audit.

When it comes to anti-doping, Cerebrolysin is not named on the WADA Prohibited List (the list of substances banned in sport). The growth-factor category (labeled S2.3 in the 2026 list) bans growth factors and modulators that affect things like muscle, tendon or ligament protein, blood-vessel growth, energy use, the ability to regenerate, or muscle fiber-type switching, with named examples including IGF-1, FGFs, HGF, MGFs, PDGF, VEGF and Thymosin-β4. Nerve growth factor and neurotrophic factors are not on that list, and the catch-all language is aimed at muscle and performance effects rather than the brain, so Cerebrolysin isn’t clearly covered. Even so, the list uses “including but not limited to” wording, and gray-market products can be contaminated, so athletes should be careful.

Bottom line

Cerebrolysin is that rare research peptide with a real body of clinical research behind it — and that is exactly what makes it so instructive. Once you set aside the manufacturer-funded studies, the post-hoc subgroups and the non-randomized cohorts, what’s left is underwhelming: the largest rigorous stroke trial came back neutral, the most independent dementia evidence is very-low-certainty and modest, and the highest-quality stroke review found no benefit for survival while flagging a possible rise in serious side effects. There is no credible support for using it as a brain enhancer in healthy people. For anyone weighing it, the honest takeaway is this: decades of study have not produced a convincing, independently repeated benefit for its headline uses, and its undefined makeup and unregulated gray-market supply pile even more uncertainty on top.

Sources

• FDA substance registry (UNII) record
• Cerebrolysin — Wikipedia
• Cerebrolysin for acute ischaemic stroke (Cochrane 2023, full text)
• Cerebrolysin for acute ischaemic stroke (Cochrane plain summary)
• Cerebrolysin for vascular dementia (Cochrane 2019)
• Cerebrolysin for vascular dementia (Cochrane plain summary)
• CASTA stroke trial (Heiss et al., Stroke 2012)
• CARS stroke-recovery trial (Muresanu et al., Stroke 2016)
• Cerebrolysin in TBI meta-analysis (Ghaffarpasand et al., 2018)
• ADDF Cognitive Vitality assessment of Cerebrolysin
• WADA Prohibited List
• WADA 2026 Prohibited List (official PDF)